Clinical trials - Press Releases

Date	Title	Company
09-Jan-2022	Registration is open for SMi’s 5th Annual Pharmaceutical Microbiology East Coast 2022	SMi Group
07-Jan-2022	The Transdermal and Microneedle Drug Delivery Virtual Conference 2022 is now only 3 weeks away!	SMi Group
05-Jan-2022	B-cell lymphoma clinical trials now open on the TrialWire Platform	TrialWire
05-Jan-2022	Autism clinical trials now open on the TrialWire Platform	TrialWire
05-Jan-2022	ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen	ProQR Therapeutics N.V.
23-Dec-2021	MHRA approves licence extension for Novartis’ targeted therapy for advanced breast cancer patients in Great Britain	Novartis
23-Dec-2021	Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalised pustular psoriasis	Boehringer Ingelheim
21-Dec-2021	Medigene AG: Medigene achieves positive preliminary results in Phase I of Phase I/II trial of TCR-T therapy MDG1011 in blood cancers	Medigene AG
21-Dec-2021	Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®	Vifor Pharma
21-Dec-2021	Almirall: Lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study	Almirall
21-Dec-2021	IACT LMC Manna Research Merges with True North Clinical Research, Boosting the Network’s Central Nervous System Disorder Capabilities	IACT LMC Manna Research
20-Dec-2021	Advancing AI Drug Discovery in Clinical Trials at SMi’s 3rd Annual AI in Drug Discovery Conference	SMi Group
20-Dec-2021	SMi’s 10th Annual Pharmaceutical Microbiology UK Conference - A Virtual Conference with Online Access Only	SMi Group
15-Dec-2021	Panthera leads the way in the UK with specialist research sites for NASH and NAFLD studies	Panthera Biopartners
15-Dec-2021	Hearing loss company Acousia Therapeutics to receive CTA for first-in-man clinical study of ACOU085	Acousia Therapeutics GmbH
15-Dec-2021	YESCARTA® (AXICABTAGENE CILOLEUCEL) ZUMA-12 STUDY DEMONSTRATES 78% COMPLETE RESPONSE RATE AS PART OF FIRST-LINE TREATMENT IN NEWLY DIAGNOSED HIGH-RISK LARGE B CELL LYMPHOMA	Kite, a Gilead Company
15-Dec-2021	4D pharma announces positive topline results from Part A of Phase I/II trial of MRx-4DP0004 for the treatment of asthma	4D pharma
15-Dec-2021	Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session	Sanofi
14-Dec-2021	Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury	Vifor Pharma and Angion
14-Dec-2021	iTeos Announces New Data for its Anti-TIGIT Antibody, EOS-448, at the American Society of Hematology Annual Meeting and TIGIT Therapies Digital Summit 2021	iTeos Therapeutics